Mutated or down-regulated in many advanced cancers [67], PTEN loss activates the PI3K-AKT [68] signaling pathway and its downstream target mTOR, with important implications in RCC development and therapeutic selection [59,60,69,70]. The gene discussed is AKT1; the disease is renal cell carcinoma.